Davidson A G
J Pharm Pharmacol. 1979 Feb;31(2):77-82. doi: 10.1111/j.2042-7158.1979.tb13436.x.
A method is described for the determination of (-)-adrenaline in certain formulations containing adrenaline hydrogen tartrate at concentrations down to 0.18 mg ml-1 (1:10 000 adrenaline). The assay is based upon a spectropolarimetric measurement at 249 nm of sample solutions, suitably treated to remove interfering substances. The rotation of the sample solutions is corrected for the rotation of the tartaric acid species which is determined by a difference rotation measurement on equimolar sample solutions at pH 1.1 and pH 5.6. The concentration of (-)-adrenaline in the sample is calculated from the net rotation at 249 nm due to the (-)-adrenaline and the total concentration of adrenaline (+)-and (-)-isomers) determined by a published spectrofluorimetric method. The assay is specific for (-)-adrenaline in the presence of (+)-adrenaline, (+)-tartaric acid, adrenaline sulphonic acid and low levels of adrenochrome.
描述了一种用于测定某些含有酒石酸氢肾上腺素的制剂中(-)-肾上腺素的方法,其浓度低至0.18 mg/ml(1:10000肾上腺素)。该测定基于对经过适当处理以去除干扰物质的样品溶液在249 nm处的旋光测定。样品溶液的旋光通过酒石酸种类的旋光进行校正,酒石酸种类的旋光通过在pH 1.1和pH 5.6的等摩尔样品溶液上进行的差示旋光测量来确定。样品中(-)-肾上腺素的浓度由249 nm处由于(-)-肾上腺素产生的净旋光以及通过已发表的荧光分光光度法测定的肾上腺素(+)-和(-)-异构体的总浓度计算得出。该测定法在(+)-肾上腺素、(+)-酒石酸、肾上腺素磺酸和低水平肾上腺色素存在的情况下对(-)-肾上腺素具有特异性。